ClinicalTrials.gg
Status unknownNCT05403814SCOBES-ARUpdated Jun 3, 2022

Test and Usability of Mixed-reality Screening Tool for Early Detection of Cognitive Declines

An observational study in Aging and Cognitive Change, sponsored by FH Joanneum Gesellschaft mbH. Status unknown at 1 site in Austria. Open to participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by FH Joanneum Gesellschaft mbH · Observational

How we know

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
60 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cognitive Dysfunction with a site in Austria — 5 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Austria.

Planned enrollment
9th of 10
100 · median 223
Started
2022
the only one that year
Observational
10 of 18
4 open now
Registered
12th of 18
by date
Lead sponsor
2 of 18
FH Joanneum Gesellschaft mbH

Among the 18 studies in Cognitive Dysfunction with a site in Austria, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 12th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

5 of the 18 studies in Cognitive Dysfunction with a site in Austria are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cognitive Dysfunction with a site in Austria, or all of them as a file.
02

Study summary

The aim of this study as part of the SCOBES-AR project is to establish and test a protocol for implementation and usability of mixed reality-enhanced multidisciplinary screening tool for early detection of cognitive impairments in the elderly.

Read the detailed description

Early diagnosis of cognitive impairments is an important step in the adequate management of dementia. The project "Smart Cognition \& Behavior Screening powered by Augmented Reality" (SCOBES-AR) aims to develop a multimodal screening tool (MST) for early detection of cognitive impairments using augmented and virtual reality. In the first project phase validated assessments were selected, combined in MST and tested in 174 healthy elderly adults. In the present project phase, the developed MST will be partly enhanced by mixed reality (MR). This MR-enhanced prototype of screening tool (MR-MST) will be tested and compared to the previously developed MST. In addition, the usability of this enhanced prototype will be examined.

The study aims to establish a protocol for implementation and usability of MR-enhanced multidisciplinary screening tool for early detection of cognitive impairments in the elderly.

In this cross-over design study protocol 100 healthy participants (aged 60-75years) will be screened for cognitive declines using: i) specially developed MST (assessment of cognitive functions, olfactory sensitivity, nutritional preferences, gait parameters, reaction times, activities of daily living, and ii) MR-enhanced MST in which the assessments of cognitive functions, reaction time, activities of daily living and gait are performed using tailor made software and augmented reality and virtual reality hardware. The results of the MR-enhanced MST will be compared with those without MR. The usability of the developed MR-enhanced MST will be tested on 10 investigators and 10 test participants using observed summative evaluation and the co-discovery method and on 2 usability experts using the co-discovery method.

This study was funded by the Austrian Research Promotion Agency and received Ethic Vote from the Ethic committee of the Medical University of Graz. The MR-MST prototype and the study protocol for the present study were developed. To date, no results are available for this study protocol.

The development of the MR-MST prototype enables identifying best practise procedure for evaluating cognitive declines in the elderly using multimodal and MR-enhanced model.

03

Conditions studied

  • Aging
  • Cognitive Change

Keywords

  • mixed reality
  • multimodal screening
  • cognitive impairment
  • smart cognition
04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Residents of the city of Graz and Graz suburbs

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy individuals aged 60-75 years
  • Interest in participating in the study
  • Signed written form

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of mild cognitive impairment or dementia
  • Clinical diagnosis of mental illness (e.g. depression, psychosis)
  • Reduced mobility (walking aid, wheelchair)
  • Aided hearing or visual impairment
  • Participation in any other cognitive training study within the last 6 months
  • Present guardianship according to the provisions of the Austrian adult protection law
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Otherobservational screening procedure (no intervention)

    observational screening procedure (no intervention)

06

What researchers measure

Primary outcomes

  1. Brief Smell Identification Test.

    The test evaluates the olfactory functions. Scale 0-12 points: higher values indicate better olfactory performance.

    Time frame: Day 1.

  2. Food-Frequency-Index.

    This assessment evaluates the dietary behavior. Dietary behavior is classified as poor (\< 32 points), moderate (32-34 points), good (35-39 points), and very good (\> 39 points).

    Time frame: Day 1.

  3. Dementia-Detection-Test.

    The test evaluates the cognitive functions (recall of word list, number transcoding, semantic word fluency, digit span reverse). Scale 0-18 points: probability of dementia (0-8 points), light cognitive changes (9-12 points), healthy (13-18 points).

    Time frame: Day 1.

  4. Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment: items "mobility" and "finances", performed with pen-and-paper.

    For each of the 2 items ("mobility" and "finances") a score 0-6 points is given. Higher score indicates better performance.

    Time frame: Day 1.

  5. Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment: items "mobility" and "finances", performed with Virtual Reality.

    For each of the 2 items ("mobility" and "finances") a score 0-6 points is given using tailor-made software. Higher score indicates better performance.

    Time frame: Day 1.

  6. Trail-Making Test, performed with pen-and-paper.

    The test evaluates the cognitive abilities and consists of two parts: connecting numbers and connecting numbers and letters in ascending order. The time (sec.) to perform the task is measured using a stop watch. Shorter time indicates better performance.

    Time frame: Day 1.

  7. Trail-Making Test, performed with Augmented Reality.

    The test evaluates the cognitive abilities and consists of two parts: connecting numbers and connecting numbers and letters in ascending order. The time (sec.) to perform the task is measured using a tailor-made software. Shorter time indicates better performance.

    Time frame: Day 1.

  8. Reaction Time Test, performed with contact plates.

    The test evaluates the complex reactivity (eye-hand, eye-leg and eye-hand-leg reactions) in response to visual signals displayed in a randomized order. The time (sec.) to perform the task is measured using a stop watch. Shorter time indicates better performance.

    Time frame: Day 1.

  9. Reaction Time Test, performed with smartphone mobile application.

    The test evaluates the complex reactivity (eye-hand, eye-leg and eye-hand-leg reactions) in response to visual signals displayed in a randomized order. The time (sec.) to perform the task is measured using mobile application. Shorter time indicates better performance.

    Time frame: Day 1.

  10. Dual Task Assessments, performed with direct observation.

    The assessment measures the influence of a cognitive task on gait parameters. Time to complete the task (sec.), number of steps and walking speed (steps/min.) will be calculated for the single task (walking) and the double task (walking and counting). Bigger difference between the parameters in both tasks indicates cognitive declines.

    Time frame: Day 1.

  11. Dual Task Assessments, performed with Augmented Reality.

    The assessment measures the influence of a cognitive task on gait parameters. Time to complete the task (sec.), number of steps and walking speed (steps/min.) will be calculated for the single task (walking) and the double task (walking and counting) using tailor-made software. Bigger difference between the parameters in both tasks indicates cognitive declines.

    Time frame: Day 1.

Secondary outcomes

  1. Usability evaluation using video observations.

    Videos of the test procedure obtained from the target groups will be evaluated by usability experts. The video observations will be evaluated using the "Eisenhower's Urgent/Important Principle", in which items are evaluated as: "not urgent" - "urgent" and as "not important" - "important", whereby the "urgent" and the "important" items indicate higher needs of improvement.

    Time frame: Day 1.

  2. Usability evaluation using questionnaire.

    Questionnaire addressing the personal experience with the screening procedure will be obtained from the target groups and will be evaluated by usability experts. The questionnaires will be evaluated using a score system (1-5), where 1 indicates very good usability.

    Time frame: Day 1.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jul 2022, 3 months after the start.

Of 545 observational studies under Cognitive Dysfunction, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 118. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2022
First posted
Jun 3, 2022
StartActual
Apr 25, 2022
Primary completionEst.
Jul 2022
CompletionEst.
Oct 2022
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05403814
Lead sponsor
FH Joanneum Gesellschaft mbH
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Apr 25, 2022
Primary completion
Jul 2022 (estimated)
Completion
Oct 2022 (estimated)
Last update
Jun 3, 2022

Study contacts

Wolfgang Staubmann, MSc
Contact
wolfgang.staubmann@fh-joanneum.at
+43 (0)316 5453 6768
Wolfgang Staubmann, MSc
principal investigator · FH Joanneum

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion